Progression and treatment of HER2-positive breast cancer April DavoliBarbara A. HocevarThomas L. Brown Mini Review 20 December 2009 Pages: 611 - 623
Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents Terence O’ReillyPaul M. J. McSheehyH. A. Lane Original Article 27 September 2009 Pages: 625 - 639
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial Joung-Soon JangHo Yeong LimSang Jae Lee Original Article 04 August 2009 Pages: 641 - 647
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer George FountzilasAnna FragkoulidiMarios Marselos Original Article 05 August 2009 Pages: 649 - 660
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients Julie FidlerovaPetra KleiblovaZdenek Kleibl Original Article 01 August 2009 Pages: 661 - 669
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991) Alexander M. M. EggermontMarna G. BouwhuisChristine Xu Original Article 21 July 2009 Pages: 671 - 677
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer Gabriella FerrandinaValentina MeyMario Del Tacca Original Article 29 July 2009 Pages: 679 - 686
RETRACTED ARTICLE: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis Nidhi NigamJasmine GeorgeYogeshwer Shukla Original Article 24 July 2009 Pages: 687 - 696
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells Tuba OzbayDonald L. DurdenRita Nahta Original Article Open access 28 July 2009 Pages: 697 - 706
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo Jennifer P. ArbitrarioBrian J. BelmontPietro Taverna Original Article 01 August 2009 Pages: 707 - 717
Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam. Hironori IwasakiTakafumi OkabeHirosuke Oku Original Article 23 July 2009 Pages: 719 - 726
Evaluation of the exposure equivalence of oral versus intravenous temozolomide Blanca D. DiezPaul StatkevichFabio H. Ottaviano Original Article Open access 30 July 2009 Pages: 727 - 734
Molecular determinants of folate levels after leucovorin administration in colorectal cancer Sotaro SadahiroToshiyuki SuzukiToshinori Oka Original Article 28 July 2009 Pages: 735 - 742
Population pharmacokinetic model of PI-88, a heparanase inhibitor Susan F. HudachekS. Gail EckhardtDaniel L. Gustafson Original Article 25 July 2009 Pages: 743 - 753
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes Alison JonesMary O’BrienVéronique Trillet-Lenoir Original Article 09 August 2009 Pages: 755 - 763
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Paul HaluskaFrank WordenGary D. Hammer Original Article 02 August 2009 Pages: 765 - 773
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy Noelle K. LoConteMaureen SmithKyle D. Holen Original Article 01 August 2009 Pages: 775 - 780
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial Delphine RollandVincent RibragCatherine Thieblemont Clinical Trial Report 04 December 2009 Pages: 781 - 790
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors Michael B. JamesonDanny RischinWilliam R. Wilson Clinical Trial Report 10 December 2009 Pages: 791 - 801
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease Tomoya FukuiSakiko OtaniNoriyuki Masuda Short Communication 25 December 2009 Pages: 803 - 806
Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer Nariaki TomiyamaMuneaki HidakaChizuko Nakamura Short Communication 27 December 2009 Pages: 807 - 809
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy P. MathewN. TannirL. Pagliaro Short Communication 06 January 2010 Pages: 811 - 815